ABCELY

Abcely's mission is to revolutionize the treatment of mucosal cancers, endometriosis, and inflammatory bowel diseases by pioneering innovative medical and pharmaceutical technologies. With a focus on providing new hope for patients facing therapeutic dead ends, Abcely introduces a groundbreaking concept in immunotherapy. At the heart of this innovation is the use of a novel class of orally active therapeutic molecules: class A immunoglobulins (sIgA). Abcely is committed to advancing these treatments through every stage of development—from identifying active compounds to proving their efficacy in human clinical trials—ensuring a transformative impact on patient care.